<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581684</url>
  </required_header>
  <id_info>
    <org_study_id>1308.1</org_study_id>
    <secondary_id>2011-004840-23</secondary_id>
    <nct_id>NCT01581684</nct_id>
  </id_info>
  <brief_title>Safety Tolerability and Pharmacokinetic of BI 411034</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 411034 (PIB) in Healthy Male Volunteers (Randomised, Single-blind, Placebocontrolled Within Dose Groups, Phase I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of the current study is to investigate the safety, tolerability and
      pharmacokinetics of BI 411034 in healthy male volunteers following oral administration of
      single rising doses.

      The secondary objective is to explore dose proportionality of BI 411034 in CYP2C19
      (Cytochrome P450) genotyped extensive metabolisers (EM).

      Another objective is to compare the safety and pharmacokinetic profiles between two different
      groups of CYP2C19 genotyped subjects, extensive metabolisers (EM) and poor metabolisers (PM)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2012</start_date>
  <completion_date type="Actual">August 1, 2012</completion_date>
  <primary_completion_date type="Actual">August 1, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Drug Related AEs</measure>
    <time_frame>From drug administration until end of trial examination, up to 13 days</time_frame>
    <description>Number of participants with drug related adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically Relevant Abnormalities for Physical Examinations, Vital Signs, ECG, Laboratory Tests</measure>
    <time_frame>From drug administration until end of trial examination, up to 13 days</time_frame>
    <description>Clinically relevant abnormalities for physical examinations, vital signs (blood pressure, pulse rate, oral body temperature, orthostasis test), 12-lead electrocardiogram (ECG) and clinical laboratory tests. Clinically relevant abnormalities are reported by the investigator as adverse events (AEs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Measured Concentration (Cmax )</measure>
    <time_frame>2 hours (h) before drug administration and 10 minutes (min), 20min, 30min, 45min, 1h 15min, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, and 72h after drug administration</time_frame>
    <description>Maximum measured concentration of the analyte (BI 411034) in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Measured Concentration (Tmax)</measure>
    <time_frame>2 hours (h) before drug administration and 10 minutes (min), 20min, 30min, 45min, 1h 15min, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, and 72h after drug administration</time_frame>
    <description>Time from dosing to maximum measured concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From 0 Extrapolated to Infinity (AUC0-infinity)</measure>
    <time_frame>2 hours (h) before drug administration and 10 minutes (min), 20min, 30min, 45min, 1h 15min, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, and 72h after drug administration</time_frame>
    <description>Area under the concentration-time curve of the analyte (BI 411034) in plasma over the time interval from 0 extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Analyte Eliminated in Urine From 0h to 4h (Ae0-4)</measure>
    <time_frame>2 hours (h) before drug administration and 10 minutes (min), 20min, 30min, 45min, 1h 15min, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, and 72h after drug administration</time_frame>
    <description>Amount of analyte (BI 411034) eliminated in urine from the time point 0h to time point 4h.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 411034 low dose - group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 411034 low dose - group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 411034 medium dose - group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 411034 medium dose - group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 411034 medium dose - group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 411034 high dose - group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 411034 high dose - group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 411034 high dose - group 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Solution for oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Solution for oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 411034</intervention_name>
    <description>Low dose solution for oral administration</description>
    <arm_group_label>BI 411034 low dose - group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solution for oral administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 411034</intervention_name>
    <description>Medium dose solution for oral administration</description>
    <arm_group_label>BI 411034 medium dose - group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 411034</intervention_name>
    <description>Low dose solution for oral administration</description>
    <arm_group_label>BI 411034 low dose - group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 411034</intervention_name>
    <description>High dose solution for oral administration</description>
    <arm_group_label>BI 411034 high dose - group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 411034</intervention_name>
    <description>High dose solution for oral administration</description>
    <arm_group_label>BI 411034 high dose - group 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 411034</intervention_name>
    <description>Medium dose solution for oral administration</description>
    <arm_group_label>BI 411034 medium dose - group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 411034</intervention_name>
    <description>High dose solution for oral administration</description>
    <arm_group_label>BI 411034 high dose - group 8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 411034</intervention_name>
    <description>Medium dose solution for oral administration</description>
    <arm_group_label>BI 411034 medium dose - group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        1. Healthy male subjects

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1308.1.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ingelheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <results_first_submitted>March 13, 2014</results_first_submitted>
  <results_first_submitted_qc>March 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 17, 2014</results_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo EM</title>
          <description>A powder for oral solution in the same volume as the respective active medication group and participants who are extensive metabolisers (EM)</description>
        </group>
        <group group_id="P2">
          <title>2mg EM</title>
          <description>Single oral dose of 2mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="P3">
          <title>8mg EM</title>
          <description>Single oral dose of 8mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="P4">
          <title>20mg EM</title>
          <description>Single oral dose of 20mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="P5">
          <title>40mg EM</title>
          <description>Single oral dose of 40mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="P6">
          <title>80mg EM</title>
          <description>Single oral dose of 80mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="P7">
          <title>150mg EM</title>
          <description>Single oral dose of 150mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="P8">
          <title>250mg EM</title>
          <description>Single oral dose of 250mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="P9">
          <title>Placebo PM</title>
          <description>A powder for oral solution in the same volume as the respective active medication group and participants who are poor metabolisers (PM)</description>
        </group>
        <group group_id="P10">
          <title>20/60mg PM</title>
          <description>Single oral dose of 20/60mg of BI 411034 for participants who are poor metabolisers</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other reason not defined</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo EM</title>
          <description>A powder for oral solution in the same volume as the respective active medication group and participants who are extensive metabolisers (EM)</description>
        </group>
        <group group_id="B2">
          <title>2mg EM</title>
          <description>Single oral dose of 2mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="B3">
          <title>8mg EM</title>
          <description>Single oral dose of 8mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="B4">
          <title>20mg EM</title>
          <description>Single oral dose of 20mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="B5">
          <title>40mg EM</title>
          <description>Single oral dose of 40mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="B6">
          <title>80mg EM</title>
          <description>Single oral dose of 80mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="B7">
          <title>150mg EM</title>
          <description>Single oral dose of 150mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="B8">
          <title>250mg EM</title>
          <description>Single oral dose of 250mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="B9">
          <title>Placebo PM</title>
          <description>A powder for oral solution in the same volume as the respective active medication group and participants who are poor metabolisers (PM)</description>
        </group>
        <group group_id="B10">
          <title>20/60mg PM</title>
          <description>Single oral dose of 20/60mg of BI 411034 for participants who are poor metabolisers</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="1"/>
            <count group_id="B10" value="5"/>
            <count group_id="B11" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.4" spread="6.3"/>
                    <measurement group_id="B2" value="35.5" spread="9.9"/>
                    <measurement group_id="B3" value="39.8" spread="4.3"/>
                    <measurement group_id="B4" value="38.8" spread="8.7"/>
                    <measurement group_id="B5" value="38.3" spread="8.2"/>
                    <measurement group_id="B6" value="39.5" spread="3.1"/>
                    <measurement group_id="B7" value="32.7" spread="5.4"/>
                    <measurement group_id="B8" value="43.8" spread="6.7"/>
                    <measurement group_id="B9" value="31.0">Measure of dispersion not possible to calculated for one participant</measurement>
                    <measurement group_id="B10" value="42.4" spread="8.6"/>
                    <measurement group_id="B11" value="38.6" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Measured Concentration (Cmax )</title>
        <description>Maximum measured concentration of the analyte (BI 411034) in plasma</description>
        <time_frame>2 hours (h) before drug administration and 10 minutes (min), 20min, 30min, 45min, 1h 15min, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, and 72h after drug administration</time_frame>
        <population>PK analysis set which included all subjects who were administered trial medication and were documented to have taken the dose of investigational treatment and who provided at least one observation for at least one pharmacokinetic (PK) endpoint without important protocol violations relevant to the evaluation of PK</population>
        <group_list>
          <group group_id="O1">
            <title>2mg EM</title>
            <description>Single oral dose of 2mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O2">
            <title>8mg EM</title>
            <description>Single oral dose of 8mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O3">
            <title>20mg EM</title>
            <description>Single oral dose of 20mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O4">
            <title>40mg EM</title>
            <description>Single oral dose of 40mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O5">
            <title>80mg EM</title>
            <description>Single oral dose of 80mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O6">
            <title>150mg EM</title>
            <description>Single oral dose of 150mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O7">
            <title>250mg EM</title>
            <description>Single oral dose of 250mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O8">
            <title>20mg PM</title>
            <description>Single oral dose of 20mg of BI 411034 for participants who are poor metabolisers</description>
          </group>
          <group group_id="O9">
            <title>60mg PM</title>
            <description>Single oral dose of 60mg of BI 411034 for participants who are poor metabolisers</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Measured Concentration (Cmax )</title>
          <description>Maximum measured concentration of the analyte (BI 411034) in plasma</description>
          <population>PK analysis set which included all subjects who were administered trial medication and were documented to have taken the dose of investigational treatment and who provided at least one observation for at least one pharmacokinetic (PK) endpoint without important protocol violations relevant to the evaluation of PK</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7" spread="34.0"/>
                    <measurement group_id="O2" value="236" spread="55.9"/>
                    <measurement group_id="O3" value="566" spread="22.0"/>
                    <measurement group_id="O4" value="629" spread="53.9"/>
                    <measurement group_id="O5" value="2630" spread="38.8"/>
                    <measurement group_id="O6" value="4610" spread="51.4"/>
                    <measurement group_id="O7" value="6600" spread="15.3"/>
                    <measurement group_id="O8" value="935" spread="17.1"/>
                    <measurement group_id="O9" value="2890" spread="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Measured Concentration (Tmax)</title>
        <description>Time from dosing to maximum measured concentration</description>
        <time_frame>2 hours (h) before drug administration and 10 minutes (min), 20min, 30min, 45min, 1h 15min, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, and 72h after drug administration</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>2mg EM</title>
            <description>Single oral dose of 2mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O2">
            <title>8mg EM</title>
            <description>Single oral dose of 8mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O3">
            <title>20mg EM</title>
            <description>Single oral dose of 20mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O4">
            <title>40mg EM</title>
            <description>Single oral dose of 40mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O5">
            <title>80mg EM</title>
            <description>Single oral dose of 80mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O6">
            <title>150mg EM</title>
            <description>Single oral dose of 150mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O7">
            <title>250mg EM</title>
            <description>Single oral dose of 250mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O8">
            <title>20mg PM</title>
            <description>Single oral dose of 20mg of BI 411034 for participants who are poor metabolisers</description>
          </group>
          <group group_id="O9">
            <title>60mg PM</title>
            <description>Single oral dose of 60mg of BI 411034 for participants who are poor metabolisers</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Measured Concentration (Tmax)</title>
          <description>Time from dosing to maximum measured concentration</description>
          <population>PK analysis set</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="0.5" upper_limit="0.52"/>
                    <measurement group_id="O2" value="0.63" lower_limit="0.48" upper_limit="1.50"/>
                    <measurement group_id="O3" value="0.63" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.75" upper_limit="1.50"/>
                    <measurement group_id="O5" value="0.62" lower_limit="0.33" upper_limit="0.75"/>
                    <measurement group_id="O6" value="0.62" lower_limit="0.48" upper_limit="1.02"/>
                    <measurement group_id="O7" value="0.63" lower_limit="0.50" upper_limit="0.77"/>
                    <measurement group_id="O8" value="0.75" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O9" value="0.50" lower_limit="0.33" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve From 0 Extrapolated to Infinity (AUC0-infinity)</title>
        <description>Area under the concentration-time curve of the analyte (BI 411034) in plasma over the time interval from 0 extrapolated to infinity</description>
        <time_frame>2 hours (h) before drug administration and 10 minutes (min), 20min, 30min, 45min, 1h 15min, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, and 72h after drug administration</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>2mg EM</title>
            <description>Single oral dose of 2mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O2">
            <title>8mg EM</title>
            <description>Single oral dose of 8mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O3">
            <title>20mg EM</title>
            <description>Single oral dose of 20mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O4">
            <title>40mg EM</title>
            <description>Single oral dose of 40mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O5">
            <title>80mg EM</title>
            <description>Single oral dose of 80mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O6">
            <title>150mg EM</title>
            <description>Single oral dose of 150mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O7">
            <title>250mg EM</title>
            <description>Single oral dose of 250mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O8">
            <title>20mg PM</title>
            <description>Single oral dose of 20mg of BI 411034 for participants who are poor metabolisers</description>
          </group>
          <group group_id="O9">
            <title>60mg PM</title>
            <description>Single oral dose of 60mg of BI 411034 for participants who are poor metabolisers</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve From 0 Extrapolated to Infinity (AUC0-infinity)</title>
          <description>Area under the concentration-time curve of the analyte (BI 411034) in plasma over the time interval from 0 extrapolated to infinity</description>
          <population>PK analysis set</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" spread="54.3"/>
                    <measurement group_id="O2" value="729" spread="96.4"/>
                    <measurement group_id="O3" value="1410" spread="18.1"/>
                    <measurement group_id="O4" value="1900" spread="66.2"/>
                    <measurement group_id="O5" value="6140" spread="53.6"/>
                    <measurement group_id="O6" value="13300" spread="70.6"/>
                    <measurement group_id="O7" value="19700" spread="47.7"/>
                    <measurement group_id="O8" value="6240" spread="14.8"/>
                    <measurement group_id="O9" value="18500" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Analyte Eliminated in Urine From 0h to 4h (Ae0-4)</title>
        <description>Amount of analyte (BI 411034) eliminated in urine from the time point 0h to time point 4h.</description>
        <time_frame>2 hours (h) before drug administration and 10 minutes (min), 20min, 30min, 45min, 1h 15min, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, and 72h after drug administration</time_frame>
        <population>PK analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>2mg EM</title>
            <description>Single oral dose of 2mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O2">
            <title>8mg EM</title>
            <description>Single oral dose of 8mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O3">
            <title>20mg EM</title>
            <description>Single oral dose of 20mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O4">
            <title>40mg EM</title>
            <description>Single oral dose of 40mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O5">
            <title>80mg EM</title>
            <description>Single oral dose of 80mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O6">
            <title>150mg EM</title>
            <description>Single oral dose of 150mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O7">
            <title>250mg EM</title>
            <description>Single oral dose of 250mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O8">
            <title>20mg PM</title>
            <description>Single oral dose of 20mg of BI 411034 for participants who are poor metabolisers</description>
          </group>
          <group group_id="O9">
            <title>60mg PM</title>
            <description>Single oral dose of 60mg of BI 411034 for participants who are poor metabolisers</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Analyte Eliminated in Urine From 0h to 4h (Ae0-4)</title>
          <description>Amount of analyte (BI 411034) eliminated in urine from the time point 0h to time point 4h.</description>
          <population>PK analysis set</population>
          <units>nmol</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="5"/>
                <count group_id="O9" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.6" spread="50.3"/>
                    <measurement group_id="O2" value="290" spread="22.1"/>
                    <measurement group_id="O3" value="530" spread="38.2"/>
                    <measurement group_id="O4" value="860" spread="34.1"/>
                    <measurement group_id="O5" value="2070" spread="38.8"/>
                    <measurement group_id="O6" value="3390" spread="44.6"/>
                    <measurement group_id="O7" value="4520" spread="25.9"/>
                    <measurement group_id="O8" value="1220" spread="30.3"/>
                    <measurement group_id="O9" value="3080" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Drug Related AEs</title>
        <description>Number of participants with drug related adverse events (AEs)</description>
        <time_frame>From drug administration until end of trial examination, up to 13 days</time_frame>
        <population>Treated set which included all subjects who were administered trial medication and were documented to have taken the dose of investigational treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo EM</title>
            <description>A powder for oral solution in the same volume as the respective active medication group and participants who are extensive metabolisers (EM)</description>
          </group>
          <group group_id="O2">
            <title>2mg EM</title>
            <description>Single oral dose of 2mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O3">
            <title>8mg EM</title>
            <description>Single oral dose of 8mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O4">
            <title>20mg EM</title>
            <description>Single oral dose of 20mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O5">
            <title>40mg EM</title>
            <description>Single oral dose of 40mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O6">
            <title>80mg EM</title>
            <description>Single oral dose of 80mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O7">
            <title>150mg EM</title>
            <description>Single oral dose of 150mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O8">
            <title>250mg EM</title>
            <description>Single oral dose of 250mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O9">
            <title>Placebo PM</title>
            <description>A powder for oral solution in the same volume as the respective active medication group and participants who are poor metabolisers (PM)</description>
          </group>
          <group group_id="O10">
            <title>20mg PM</title>
            <description>Single oral dose of 20mg of BI 411034 for participants who are poor metabolisers</description>
          </group>
          <group group_id="O11">
            <title>60mg PM</title>
            <description>Single oral dose of 60mg of BI 411034 for participants who are poor metabolisers</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Drug Related AEs</title>
          <description>Number of participants with drug related adverse events (AEs)</description>
          <population>Treated set which included all subjects who were administered trial medication and were documented to have taken the dose of investigational treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinically Relevant Abnormalities for Physical Examinations, Vital Signs, ECG, Laboratory Tests</title>
        <description>Clinically relevant abnormalities for physical examinations, vital signs (blood pressure, pulse rate, oral body temperature, orthostasis test), 12-lead electrocardiogram (ECG) and clinical laboratory tests. Clinically relevant abnormalities are reported by the investigator as adverse events (AEs).</description>
        <time_frame>From drug administration until end of trial examination, up to 13 days</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo EM</title>
            <description>A powder for oral solution in the same volume as the respective active medication group and participants who are extensive metabolisers (EM)</description>
          </group>
          <group group_id="O2">
            <title>2mg EM</title>
            <description>Single oral dose of 2mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O3">
            <title>8mg EM</title>
            <description>Single oral dose of 8mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O4">
            <title>20mg EM</title>
            <description>Single oral dose of 20mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O5">
            <title>40mg EM</title>
            <description>Single oral dose of 40mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O6">
            <title>80mg EM</title>
            <description>Single oral dose of 80mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O7">
            <title>150mg EM</title>
            <description>Single oral dose of 150mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O8">
            <title>250mg EM</title>
            <description>Single oral dose of 250mg of BI 411034 for participants who are extensive metabolisers</description>
          </group>
          <group group_id="O9">
            <title>Placebo PM</title>
            <description>A powder for oral solution in the same volume as the respective active medication group and participants who are poor metabolisers (PM)</description>
          </group>
          <group group_id="O10">
            <title>20mg PM</title>
            <description>Single oral dose of 20mg of BI 411034 for participants who are poor metabolisers</description>
          </group>
          <group group_id="O11">
            <title>60mg PM</title>
            <description>Single oral dose of 60mg of BI 411034 for participants who are poor metabolisers</description>
          </group>
        </group_list>
        <measure>
          <title>Clinically Relevant Abnormalities for Physical Examinations, Vital Signs, ECG, Laboratory Tests</title>
          <description>Clinically relevant abnormalities for physical examinations, vital signs (blood pressure, pulse rate, oral body temperature, orthostasis test), 12-lead electrocardiogram (ECG) and clinical laboratory tests. Clinically relevant abnormalities are reported by the investigator as adverse events (AEs).</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="1"/>
                <count group_id="O10" value="5"/>
                <count group_id="O11" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From drug administration until end of trial examination, up to 13 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo EM</title>
          <description>A powder for oral solution in the same volume as the respective active medication group and participants who are extensive metabolisers (EM)</description>
        </group>
        <group group_id="E2">
          <title>2mg EM</title>
          <description>Single oral dose of 2mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="E3">
          <title>8mg EM</title>
          <description>Single oral dose of 8mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="E4">
          <title>20mg EM</title>
          <description>Single oral dose of 20mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="E5">
          <title>40mg EM</title>
          <description>Single oral dose of 40mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="E6">
          <title>80mg EM</title>
          <description>Single oral dose of 80mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="E7">
          <title>150mg EM</title>
          <description>Single oral dose of 150mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="E8">
          <title>250mg EM</title>
          <description>Single oral dose of 250mg of BI 411034 for participants who are extensive metabolisers</description>
        </group>
        <group group_id="E9">
          <title>Placebo PM</title>
          <description>A powder for oral solution in the same volume as the respective active medication group and participants who are poor metabolisers (PM)</description>
        </group>
        <group group_id="E10">
          <title>20mg PM</title>
          <description>Single oral dose of 20mg of BI 411034 for participants who are poor metabolisers</description>
        </group>
        <group group_id="E11">
          <title>60mg PM</title>
          <description>Single oral dose of 60mg of BI 411034 for participants who are poor metabolisers</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Chromatopsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling drunk</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

